Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Issues relating to FDA compounding regulations.
Issues relating to illegal marketing of phenobarbital
Issues relating to FDA approval of adrenaline
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Treatment of inbound companies in comprehensive tax reform; Treasury regulations relating to Section 385.
Duration: November 15, 2008
to
February 28, 2018
General Issues: Health Issues , Taxation/Internal Revenue Code , Pharmacy , Copyright/Patent/Trademark , Medicare/Medicaid
Spending: about $1,384,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Bill K. Brewster
US Congress '91-'97
US House of Representatives '91-'97
Steve Irizarry
1/92 6/92. Intern, Rep. Jim Kolbe (R-AZ); 11/97 10/98
Health Counsel, House Commerce Committee Rep. Bliley;
4/99 4/01 Health Counsel, Sen. Hagel; 5/01 1/05 Health
Counsel-Sen Health, Educ. Labor, Pens. Committee- Sen. Gregg
2/05 9/05 Health Counsel, Senate Aging Committee,
Senator Smith
1/92-6/92 Intern for Rep. Kolbe; 11/97-10/98
Health Counsel House Commerce Committee for
Rep. Bliley; 4/99-4/01 Health Counsel for Senator
Hagel; 5/01-1/05 Health Counsel for Senator
Gregg; 2/05-9/05 Health Counsel for Sen. Smith
Rep. Bliley; 4/99-4/01 Health Counsel Sen. Hagel
5/01-1/05 Health Counsel- Senate Health, Educa.
Labor, Pension Committe Sen. Gregg; 2/05-9/05
Health Counsel, Senate Aging Committee Sen.
Intern for Rep. Kolbe 1/92-6/92; Health Counsel
House Commerce Committe Rep Bliley 11/97-
10/98; Health Counsel Sen. Hagel 4/99-4/01;
Health Counsel-Senate Health, Education, Labor,
Pension Committee Sen. Gregg 5/01-1/05; Health
Counsel, Senate Aging Committee Sen. Smith
Hagel; 5/01-1/05 Health Counsel for Sen. Gregg;
1/92-6/92 Intern for Rep. Kolbe (R-AZ); 11/97-
10/98 Health Counsel, House Commerce Comm.
Rp. Bliley; 4/99-4/01 Health Counsel Sen. Hagel;
5/01-1/05 Health Counsel- Senate Health, Educati
Labor, Pension Committee-Sen. Gregg; 2/05-9/05
Health Counsel, Senate Aging Committee, Senator
Brian Sutter
Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14
Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13
Leg Dir. Rep. Dave Camp, May'08-Jan'11
Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02
Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14
Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13
Leg Dir. Rep. Dave Camp, May'08-Jan'11
Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02-
Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
William Steve Southerland
William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.
Tom Wharton
Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012
Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011
Chris Bowlin
Sen. McCain-Hlth and Policy Adv 2009-Aug.2013
Dept HHS- Deputy Asst Secretary for Legislation
2008-2009; Dept of Labor-Deputy Asst Secretary
for Congressional and Intergovt Affairs 2001-2002
Professional Staff-House Education and Workforc
Committee 1999-2001
Amy Shank
2005-2011 Senate HELP Cmte; Dir. of Oversight
2003-2004 Senate Budget Committee
2001-2002 Ofc. of Asst. GOP Leader Don Nickles
2005-2011 Senate HELP Cmte; Dir of Oversight
Surya Gunasekara
Chief of Staff and Tax Counsel - Rep. James B. Renacci May 2015 - Aug. 2017.
David Jory
n/a
Bill Brewster
n/a
Bill K Brewster
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2018
CAPITOL HILL CONSULTING GROUP terminated an engagement in which they represented Endo Pharmaceuticals on April 20, 2018.
Original Filing: 300954237.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Issues relating to FDA compounding regulations.
Issues relating to illegal marketing of phenobarbital
Issues relating to FDA approval of adrenaline
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Treatment of inbound companies in comprehensive tax reform; Treasury regulations relating to Section 385.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934884.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Issues relating to FDA compounding regulations.
Issues relating to illegal marketing of phenobarbital
Issues relating to FDA approval of adrenaline
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Treatment of inbound companies in comprehensive tax reform; Treasury regulations relating to Section 385.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on Oct. 19, 2017.
Original Filing: 300910100.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Treatment of inbound companies in comprehensive tax reform; Treasury regulations relating to Section 385.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Endo Pharmaceuticals in Q32017 on Oct. 19, 2017.
Original Filing: 300910751.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Issues relating to FDA compounding regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Treatment of inbound companies in comprehensive tax reform; Treasury regulations relating to Section 385.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300895216.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300876732.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
Issues relating to products containing high doses of acetaminophen.
Issues relating to removal of FDA unapproved products from the market
Opioid abuse legislation
Issues relating to prescription drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation/Internal Revenue Code
Issues relating to incentives for life sciences research.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on Jan. 20, 2017.
Original Filing: 300853172.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues)
H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market
HR 5046/S 524 - Opioid abuse legislation
H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160 - Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300838093.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues)
H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market
HR 5046/S 524 - Opioid abuse legislation
H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160 - Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300820025.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues)
H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market
HR 5046/S 524 - Opioid abuse legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research.
H.R. 160 - Protect Medical Innovation Act of 2015.
Tax treatment of inverted companies.
Tax issues in mergers and acquisitions of US firms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implementation of the America Invents Act.
Issues relating to patent settlements
H.R. 9 -- The Innovation Act
S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015
Issues relating to misuse of the inter pares review process
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2016
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on April 15, 2016.
Original Filing: 300791951.xml
Lobbying Issues
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues)
H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market
S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 160- Protect Medical Innovation Act of 2015
Issues relating to incentives for life sciences research
Tax treatment of inverted companies
Tax issues on mergers and acquisitions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781386.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
Compounding and drug supply chain legislation.
H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to the availability of epinephrine.
General Health issues, including but not limited to, coverage and reimbursement; drug
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 160- Protect Medical Innovation Act of 2015
H.Res106 Prostate Cancer Survivors Quality of Life Act
Medical Device Tax Repeal
Stop Corporate Inversions Act S.2360, H.R.4679
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implantation of the America Invents Act
Issues relating to patent settlements
H.R.9-The Innovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on Oct. 19, 2015.
Original Filing: 300758545.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
Compounding and drug supply chain legislation.
H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106;
General Health issues, including but not limited to, coverage and reimbursement; drug
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research
H.R. 160- Protect Medical Innovation Act of 2015
H.Res106 Prostate Cancer Survivors Quality of Life Act
Medical Device Tax Repeal
Stop Corporate Inversions Act S.2360, H.R.4679
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implantation of the America Invents Act
Issues relating to patent settlements
H.R.9-The Innovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $50,000. The report was filed on July 15, 2015.
Original Filing: 300734816.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
Compounding and drug supply chain legislation.
H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106;
General Health issues, including but not limited to, coverage and reimbursement; drug
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research
H.R. 160- Protect Medical Innovation Act of 2015
H.Res106 Prostate Cancer Survivors Quality of Life Act
Medical Device Tax Repeal
Stop Corporate Inversions Act S.2360, H.R.4679
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implantation of the America Invents Act
Issues relating to patent settlements
H.R.9-The Innovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $40,000. The report was filed on April 17, 2015.
Original Filing: 300719570.xml
Lobbying Issues
Issues relating to bioequivalence and related administrative procedures.
Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to Medicare Part D rebates.
Issues relating to health information technology.
Compounding and drug supply chain legislation.
H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106;
General Health issues, including but not limited to, coverage and reimbursement; drug
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to incentives for life sciences research
H.R. 160- Protect Medical Innovation Act of 2015
H.Res106 Prostate Cancer Survivors Quality of Life Act
Medical Device Tax Repeal
Stop Corporate Inversions Act S.2360, H.R.4679
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Oversight of implantation of the America Invents Act
Issues relating to patent settlements
H.R.9-The Innovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $40,000. The report was filed on Jan. 17, 2015.
Original Filing: 300699459.xml
Lobbying Issues
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Ensuring Safe Access to Prescription Medication Act of 2014 S.2825
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $40,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680399.xml
Lobbying Issues
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $30,000. The report was filed on July 14, 2014.
Original Filing: 300656286.xml
Lobbying Issues
General health issues, including, but not limited to, coverage and reimbursement; drug imporation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486); Safeguarding America's Pharmaceuticals Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medical Device Tax Repeal; Stop Corporate Inversions Act, S.2360 and H.R. 4679; issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013, S.232, H.R. 523
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $30,000. The report was filed on April 15, 2014.
Original Filing: 300636444.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Device Tax Repeal; General Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $40,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616843.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Device Tax Repeal; General Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $40,000. The report was filed on Oct. 8, 2013.
Original Filing: 300591419.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Device Tax Repeal; General Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $45,000. The report was filed on July 10, 2013.
Original Filing: 300570299.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Device Tax Repeal; General Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $45,000. The report was filed on April 17, 2013.
Original Filing: 300552259.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Device Tax Repeal; General Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $45,000. The report was filed on Jan. 16, 2013.
Original Filing: 300530262.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S. 1410; the Life Sciences Jobs and Investment Act of 2011, biosimiliars; prescription and generic drug user fees legislation; H.R. 6160, Stop Tampering of Prescription Pills Act of 2012.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $45,000. The report was filed on Oct. 10, 2012.
Original Filing: 300504982.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S. 1410; the Life Sciences Jobs and Investment Act of 2011, biosimiliars; prescription and generic drug user fees legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $32,000. The report was filed on July 12, 2012.
Original Filing: 300483159.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S. 1410; the Life Sciences Jobs and Investment Act of 2011, biosimiliars; prescription and generic drug user fees legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Endo Pharmaceuticals in Q12012 on April 11, 2012.
Original Filing: 300459209.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410; the Life Sciences Jobs and Investment Act of 2011; biosimiliars; prescription and generic drug user fees legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Endo Pharmaceuticals in Q42011 on Jan. 17, 2012.
Original Filing: 300438938.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410, the Life Sciences Jobs and Investment Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Endo Pharmaceuticals in Q32011 on Oct. 18, 2011.
Original Filing: 300418310.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; life sciences research tax credit legislation; H.R. 2632/S.1410, the Life Sciences Jobs and Investment Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $30,000. The report was filed on Oct. 13, 2011.
Original Filing: 300413125.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $30,000. The report was filed on July 19, 2011.
Original Filing: 300396002.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $30,000. The report was filed on April 19, 2011.
Original Filing: 300370248.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on Jan. 19, 2011.
Original Filing: 300346415.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313181.xml
Lobbying Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); the Pharmaceutical Market Access and Drug Safety Act (S. 525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3950)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on July 14, 2010.
Original Filing: 300286830.xml
Lobbying Issues
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on April 19, 2010.
Original Filing: 300266500.xml
Lobbying Issues
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on Jan. 8, 2010.
Original Filing: 300228321.xml
Lobbying Issues
General Healthcare issues, including but not limited to, coverage and reimbursement, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (H.R. 163); The Pharmaceutical Market Access and Drug Safety Act (S. 525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (H.R. 3200); America's Health Future Act of 2009; Affordable Healthcare for America Act (H.R.3962); Patient Protection and Affordable Care Act (H.R.3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on Oct. 6, 2009.
Original Filing: 300201096.xml
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); The Pharmaceutical Market Access and Drug Safety Act (S.525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act (HR3200); America's Health Future Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on July 13, 2009.
Original Filing: 300175518.xml
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); The Pharmaceutical Market Access and Drug Safety Act (S.525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $20,000. The report was filed on April 15, 2009.
Original Filing: 300148444.xml
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General Healthcare issues, including but not limited to, drug importation; Pharmaceutical Market Access Act (S.80); Prescription Drug Affordability Act (HR163); and The Pharmaceutical Market Access and Drug Safety Act (S.525)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General health care issues, including but not limited to, drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Endo Pharmaceuticals , earning $10,000. The report was filed on Jan. 13, 2009.
Original Filing: 300116307.xml
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement. General health care issues, including but not limited to, drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2008
Capitol Hill Consulting Group filed a lobbying registration on Dec. 9, 2008 to represent Endo Pharmaceuticals, effective Nov. 15, 2008.
Original Filing: 300112475.xml
Issue(s) they said they’d lobby about: General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General health care issues, including but not limited to, drug importation .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate